Literature DB >> 24567352

Paraoxonase lactonase activity, inflammation and antioxidant status in plasma of patients with type 1 diabetes mellitus.

Octavian Savu1, Cristian Serafinceanu, Ioana Veronica Grajdeanu, Liviu Iosif, Laura Gaman, Irina Stoian.   

Abstract

OBJECTIVES: To investigate paraoxonase-1 (PON1) lactonase activity, myeloperoxidase (MPO) activity (as a marker of inflammation) and antioxidant status in plasma of patients with type 1 diabetes mellitus.
METHODS: Whole blood and plasma samples were collected from patients with diabetes and healthy control subjects. PON1 lactonase and MPO activities and total antioxidant capacity (TEAC) were determined in plasma. Glycosylated haemoglobin (HbA1c) was quantified in whole blood.
RESULTS: Plasma PON1 lactonase and MPO activities were significantly higher and TEAC was significantly lower in patients with diabetes (n = 18) compared with healthy control subjects (n = 20). There were significant positive correlations between PON1 lactonase activity and MPO activity and HbA1c level, and plasma MPO and HbA1c. There were significant negative correlations between PON1 lactonase activity and TEAC, and MPO activity and TEAC.
CONCLUSIONS: Increased lactonase activity may inefficiently compensate for the high level of chronic inflammation and low antioxidant capacity in the plasma of patients with type 1 diabetes mellitus.

Entities:  

Keywords:  Lactonase; antioxidants; myeloperoxidase; paraoxonase; type 1 diabetes

Mesh:

Substances:

Year:  2014        PMID: 24567352     DOI: 10.1177/0300060513516287

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  2 in total

Review 1.  High-Density Lipoprotein Function and Dysfunction in Health and Disease.

Authors:  Scott T Chiesa; Marietta Charakida
Journal:  Cardiovasc Drugs Ther       Date:  2019-04       Impact factor: 3.727

2.  HDL functionality in type 1 diabetes: enhancement of cholesterol efflux capacity in relationship with decreased HDL carbamylation after improvement of glycemic control.

Authors:  Damien Denimal; Serge Monier; Isabelle Simoneau; Laurence Duvillard; Bruno Vergès; Benjamin Bouillet
Journal:  Cardiovasc Diabetol       Date:  2022-08-12       Impact factor: 8.949

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.